Latest Technology Platforms News

Atturra Limited is set to acquire DalRae Solutions, a specialist SAP consultancy, in a deal valued up to $20 million that aims to deepen its SAP capabilities and market reach.

Elders Limited has reported a robust 67% increase in underlying EBIT for the half-year ending March 2025, driven by livestock market recovery and real estate growth, alongside five new acquisitions and ongoing transformation initiatives.

Bendigo and Adelaide Bank reported a 7.8% decline in cash earnings for 3Q25, reflecting lower other income and a slight dip in net interest income, while completing its Rural Bank system migration.

Smart Parking Limited reports robust H1 FY25 growth driven by a strategic US acquisition and expanding global footprint, underpinned by proprietary AI technology.

Bell Financial Group delivered strong financial results for 2024, driven by growth in technology and product services, but early 2025 shows challenges from market volatility impacting core broking revenues.

Plenti Group Limited reported a stellar FY25 with a 126% surge in Cash NPAT to $13.8 million, driven by robust loan portfolio growth and operational efficiency. The fintech lender is targeting a $3 billion loan book by March 2026, leveraging technology and strategic partnerships.

Plenti Group Limited reported a robust FY25 with a 126% jump in Cash NPAT to $13.8 million and a 19% increase in its loan portfolio to $2.5 billion, driven by technology enhancements and strategic partnerships.

Noxopharm Limited has raised nearly $2.5 million by selling its entire stake in Nyrada Inc, providing non-dilutive capital to advance its HERACLES clinical trial and expand its research pipeline.

Gentrack reported a solid 9.8% revenue increase to NZ$112 million in HY25, driven by recurring revenue growth and international expansion, while net profit after tax surged 34.7%. The company’s outlook remains optimistic as it targets FY25 revenue above NZ$230 million and deeper market penetration across Asia, Europe, and the Middle East.

Australian Bond Exchange Holdings has completed a $683,180 private placement, issuing over 17 million shares to strengthen its financial position and support expansion and cost-cutting initiatives.

Mesoblast has been granted a seven-year orphan-drug exclusivity by the FDA for its cell therapy Ryoncil, reinforcing its market position in treating steroid-refractory acute graft versus host disease in children.

Proteomics International Laboratories has secured a key Chinese patent for its OxiDx oxidative stress test, broadening its intellectual property coverage across major global markets until 2039. This milestone reinforces the company’s position in precision diagnostics for sports and veterinary health.